Filing Flows › Industrials › Absci (ABSI)
Absci (ABSI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Absci (ABSI) Q2 2026 earnings results →
Q2 2026 Revenue down 46% year over year to $318K
Absci made $318K in Q2 2026 (-46% Y/Y). Operating margin n/m, net loss $33.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $318K in Q2 2026, down 46% year over year and up 48% from the previous quarter.
Operating costs exceeded revenue by $34.2M, an operating margin of -10741.5%. Total costs grew 8% against a revenue fall of 46%. The fastest-growing cost line was Research & development (+11%). The quarter ended with a net loss of $33.2M, wider than the previous quarter's $29.6M loss.
Operating cash flow was −$27.6M. Non-cash charges added back $2.7M of depreciation and amortization and $5.2M of share-based compensation. Working capital and other items used $2.3M. Capital expenditures of $1K exceeded it, leaving free cash flow of −$27.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 11, 2026 | $318K | -46% | n/m | −$33.2M | −$27.6M |
| Q1 2026 | 10-Q | May 7, 2026 | $215K | -82% | n/m | −$29.6M | −$26.3M |
| Q4 2025 | 10-K | Mar 24, 2026 | $650K | -2% | n/m | −$29.6M | −$29.2M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $378K | -78% | n/m | −$28.7M | −$25.0M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $593K | -53% | n/m | −$30.6M | −$16.9M |
| Q1 2025 | 10-Q | May 13, 2025 | $1.2M | +31% | n/m | −$26.3M | −$21.8M |
| Q4 2024 | 10-K | Mar 18, 2025 | $665K | +97% | n/m | −$29.0M | −$17.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Absci
We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop. We focus on underexplored mechanisms where unmet medical need is high and competition is low. We have advanced our first two programs from AI design to IND (or foreign equivalent) in around two years with a total investment of approximately $15 million per program, compared to an industry average of 4–6 years at a cost of greater than $50 million. This combination of underexplored target selection and capital-efficient execution is central to our strategy.
In its own words, from its 10-K, filed Mar 24, 2026.
Absci against its Services-Commercial Physical & Biological Research peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -46% against the peers' median +8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ABSI Absci | Q2 2026 | $318K | -46% | n/m |
| IQV IQVIA Holdings | Q3 2026 | $4.4B | +8% | 12.9% |
| INCY Incyte | Q3 2026 | $1.6B | +14% | -45.5% |
| CRL Charles River Laboratories International | Q3 2026 | $983M | -2% | 20.6% |
| MEDP Medpace Holdings | Q3 2026 | $716M | +8% | 23.1% |
| NRC NRC Health | Q3 2026 | $38.4M | +11% | 23.2% |
| MXCT Maxcyte | Q2 2026 | $7.3M | -14% | -140.7% |
| FOXO Foxo Technologies | Q2 2026 | $4.7M | -10% | 185.5% |
| OABI OmniAb | Q3 2026 | $4.0M | +78% | -409.9% |
Source: Absci 10-Q on SEC EDGAR · CIK 1672688 · Services-Commercial Physical & Biological Research
13F: who owns ABSI and who is buying
More on ABSI
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results